Fig. 2

MHCI and CTLs depletion accelerate disease onset and motor deficits but increases survival in mSOD1 mice. a Paw Grip Endurance (PaGE) test for Ntg+/+, Ntg−/−, G93A+/+ and G93A^−/− mice. Data are reported as mean ± SEM for each time point. ^***P < 0.001; ^****P < 0.0001 (G93A−/− vs G93A+/+); ^°°P < 0.001; ^°°°°P < 0.0001 (G93A−/− vs G93A+/−) by repeated measures ANOVA with Sidak’s post-analysis. b G93A−/− mice have an earlier onset of motor impairment than G93A^+/+ and G93A+/− mice. P < 0.0022 by Mantel-Cox log-rank test. c G93A^−/− mice display a trend to have delayed the onset of disability compared to G93A+/+. (P = 0.075 by Mantel-Cox log-rank test. d G93A^−/− mice display a prolonged survival in respect to G93A^+/+ and G93A+/− mice. P < 0.0001 by Mantel-Cox log-rank test. e G93A^−/− mice have longer disease duration than G93A+/+ and G93A+/− mice. Data are reported as mean ± SEM. ^****P < 0.0001 (G93A−/− vs G93A+/+; ^###P < 0.001 (G93A−/− vs G93A+/−) by one-way ANOVA with Tukey’s post-analysis. f G93A−/− mice spent on average seven days more in the cage after the onset of disability than G93A+/+ mice. ^****P < 0.0001 (G93A−/− vs G93A+/+); ^##P < 0.01 (G93A−/− vs G93A+/−) by one-way ANOVA with Tukey’s post-analysis. Data are reported as mean ± SEM. All the analysis, except the survival, were performed on n = 15 mice NTG+/+; n = 15 NTG−/− mice; n = 16 G93A+/− mice; n = 15 G93A+/+ mice and n = 15 G93A−/− mice. The overall survival was calculated on n = 22 G93A−/− and n = 20 G93A +/+ and n = 16 G93A+/− mice